Skip to main content

Table 1 Demographic and clinical data

From: Treatment responses for branch retinal vein occlusion predicted by semi-automated fluorescein angiography quantification

  All patients (n = 89) Responsive group (n = 47) Refractory group (n = 42) P value
Eye (OD : OS) 49 : 40 26 : 21 23 : 19 0.958
Age 62.5 ± 10.9 60.9 ± 11.7 64.2 ± 9.8 0.160
Sex (male : female) 56 : 33 30 : 17 26 : 16 0.851
Follow-up duration (months) 32.0 ± 21.8 30.0 ± 22.7 34.3 ± 20.8 0.348
Number of anti-VEGF injections in first year 4.1 ± 2.3 2.4 ± 1.2 5.9 ± 1.6 < 0.001
Baseline logMAR BCVA 0.88 ± 0.56 0.84 ± 0.60 0.93 ± 0.52 0.416
LogMAR BCVA at 1 year 0.60 ± 0.46 0.50 ± 0.49 0.72 ± 0.40 0.024
Pre-treatment CRT (μm) 495 ± 175 451 ± 157 544 ± 183 0.011
Post-treatment best CRT (μm) 253 ± 52 233 ± 33 275 ± 61 < 0.001
CRT at 1 year (μm) 329 ± 131 252 ± 38 414 ± 146 < 0.001
Type of BRVO (major : macular) 61 : 28 30 : 17 31 : 11 0.311
Type of macular edema on OCT     
  Cystoid macular edema (yes : no) 47 : 42 21 : 26 26 : 16 0.104
  Diffuse retinal thickening (yes : no) 41 : 48 24 : 23 17 : 25 0.317
  Serous retinal detachment (yes : no) 13 : 76 6 : 41 7 : 35 0.603
Mean gray value over parafoveal region 25.0 ± 21.1 14.1 ± 12.5 37.3 ± 22.1 < 0.001
Mean gray value over perifoveal region 23.3 ± 15.1 14.9 ± 8.9 32.7 ± 15.0 < 0.001
  1. Continuous data are presented as mean ± standard deviation
  2. Abbreviations: logMAR BCVA best-corrected visual acuity expressed in logarithm of the minimal angle of resolution; BRVO Branch Retinal Vein Occlusion; CRT central retinal thickness; FA fluorescein angiography; OCT: optical coherence tomography; VEGF vascular endothelial growth factor. Bold values indicate P < 0.05